Chronic Fatigue and Mitochondrial Dysfunction

Overview

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, multi-system disorder characterized by profound fatigue that is not relieved by rest and is worsened by physical or mental exertion. Affecting an estimated 17 to 24 million people worldwide, ME/CFS remains one of the most poorly understood conditions in medicine. The hallmark feature, post-exertional malaise (PEM), distinguishes it from ordinary fatigue and points to a fundamental impairment in how the body produces and manages energy at the cellular level.

Mitochondria, often called the powerhouses of the cell, are responsible for producing adenosine triphosphate (ATP), the primary energy currency of the body. Emerging research has consistently identified mitochondrial dysfunction as a recurring theme in the pathophysiology of ME/CFS, with evidence of impaired ATP production, elevated oxidative stress, and bioenergetic failure in affected individuals. This has led researchers to investigate mitochondrial-derived peptides (MDPs) as potential therapeutic agents.

Signs and Symptoms

ME/CFS presents with a constellation of symptoms that extend well beyond fatigue:

• Debilitating fatigue lasting six months or longer, not explained by other medical conditions
• Post-exertional malaise (PEM): disproportionate worsening of symptoms following physical or cognitive activity
• Unrefreshing sleep despite adequate duration
• Cognitive impairment, often described as "brain fog," affecting memory, concentration, and word retrieval
• Orthostatic intolerance, including dizziness upon standing
• Muscle and joint pain without swelling or redness
• Headaches of new type, pattern, or severity
• Sore throat and tender lymph nodes
• Sensitivity to light, sound, and temperature

Diagnosis remains clinical, relying entirely on symptom-specific case criteria following the exclusion of other explanatory diagnoses, as standardized biomarkers have not yet been established.

Current Research

Several mitochondrial-targeting peptides are under investigation for their potential to address the energy production deficits observed in ME/CFS.

SS-31 (Elamipretide)

SS-31, also known as elamipretide, is a four-amino-acid cell-penetrating peptide that targets the inner mitochondrial membrane, specifically binding to the phospholipid cardiolipin. This interaction stabilizes the electron transport chain and the mitochondrial machinery responsible for ATP synthesis. In September 2025, the FDA granted accelerated approval for elamipretide (marketed as Forzinity) as the first treatment for Barth syndrome, a rare mitochondrial disorder. The approval validated the peptide's mechanism of action in humans, though its application to ME/CFS specifically remains investigational. Short-term trials have shown improved exercise performance in primary mitochondrial myopathy, while evidence for general chronic fatigue remains limited.

MOTS-c

MOTS-c is a mitochondrial-derived peptide encoded by the MT-RNR1 gene within mitochondrial DNA. It has emerged as a key regulator of metabolic homeostasis, with research demonstrating its ability to enhance mitochondrial biogenesis, reduce oxidative stress, and improve cellular energy metabolism. A 2019 study published in the Journal of Translational Medicine found that the MOTS-c gene was differentially expressed in CFS patients compared to healthy controls. A 2025 review by Klimas et al. specifically outlined the case for MOTS-c as a therapeutic candidate in ME/CFS, citing its potential to address the core bioenergetic failures observed in the condition. However, exogenous administration at pharmacologic doses has not yet been evaluated in human clinical trials for this indication.

Humanin

Humanin is another mitochondrial-derived peptide, encoded by the MT-RNR2 gene, that has demonstrated cytoprotective and anti-apoptotic properties. Research has found decreased median production of humanin in CFS patients (364 pg/mL) compared to healthy controls, suggesting a possible role in disease pathophysiology. Humanin may protect against mitochondrial stress and cellular damage, but its therapeutic application in ME/CFS remains at an early investigational stage.

Management Approaches

Management of ME/CFS currently focuses on symptom relief and activity management, as no curative treatment exists:

• Activity pacing: Carefully balancing activity and rest to avoid triggering post-exertional malaise
• Sleep hygiene: Optimizing sleep environment and habits, though pharmaceutical sleep aids may be necessary
• Pain management: Over-the-counter analgesics, low-dose naltrexone, and other approaches may provide relief
• Cognitive support: Organizational tools, cognitive behavioral strategies, and workplace accommodations
• Nutritional support: Addressing deficiencies in CoQ10, B vitamins, magnesium, and other mitochondrial cofactors
• Emerging research: Mitochondrial-targeted peptides represent a promising but still investigational frontier in ME/CFS management

When to Seek Care

Seek medical attention if you experience persistent, unexplained fatigue lasting more than six months that significantly limits your daily activities, particularly if accompanied by post-exertional malaise, cognitive difficulties, or unrefreshing sleep. A thorough evaluation is important to exclude other treatable conditions such as thyroid disorders, anemia, sleep apnea, or depression. Working with a healthcare provider experienced in ME/CFS can help develop an individualized management plan.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. The peptide research discussed is largely preclinical, and these compounds have not been approved for the treatment of ME/CFS. Always consult a qualified healthcare provider before making any changes to your treatment plan.